Compare CTNT & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNT | SILO |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Apparel |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.2M |
| IPO Year | 2023 | 2011 |
| Metric | CTNT | SILO |
|---|---|---|
| Price | $2.69 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 168.3M | 1.5M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.74 | ★ 57.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,288,536.00 | $72,102.00 |
| Revenue This Year | $42.49 | $1.86 |
| Revenue Next Year | $22.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.02 | $0.22 |
| 52 Week High | $4.21 | $1.13 |
| Indicator | CTNT | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 44.15 |
| Support Level | $1.48 | $0.40 |
| Resistance Level | $4.21 | $0.47 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 64.30 | 6.48 |
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.